Related Experiment Video
Updated: Aug 18, 2025

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Naloxegol for Treatment of Opioid-Induced Constipation in the Pediatric Intensive Care Unit
Ethan L Gillett1,2, Clint A Layes1, Lee Crawley1
1Arkansas Children's Hospital, Little Rock, AR, USA.
Insights
Naloxegol effectively increased stool frequency in critically ill children with opioid-induced constipation. This treatment did not worsen opioid-withdrawal symptoms, suggesting it is a safe adjunctive therapy.
Area of Science:
- Pediatric Critical Care Medicine
- Gastroenterology
- Pharmacology
Background:
- Opioid-induced constipation (OIC) is a frequent complication in critically ill children receiving sedation.
- Naloxegol, an FDA-approved oral peripherally acting mu-opioid receptor antagonist, is used for OIC in adults, but pediatric data are limited.
Purpose of the Study:
- To evaluate the efficacy and safety of naloxegol for treating OIC in critically ill children.
Main Methods:
- Retrospective analysis of 45 critically ill children who received naloxegol for OIC.
- Assessed changes in stool frequency and Withdrawal Assessment Tool 1 (WAT-1) scores before and after naloxegol initiation.
Main Results:
- Mean stool frequency significantly increased from 0.63 to 1.71 stools/day post-naloxegol (P < .001).
- No significant difference was observed in WAT-1 scores before and after the first dose (P = .63).
Conclusions:
- Naloxegol effectively increases stool output in critically ill children with OIC.
- It appears to be a safe adjunctive therapy, as it does not increase opioid-withdrawal symptoms in this population.
Abstract:
Opioid-induced constipation is a common problem in critically ill children requiring sedation. Naloxegol is an oral U.S. Food and Drug Administration (FDA)-approved peripherally acting mu-opioid receptor antagonist for chronic opioid-induced constipation use in adults, but data on its use in children are lacking. We performed a retrospective analysis of critically ill children that had received naloxegol for opioid-induced constipation at our institution. Of the 45 patients studied, mean stool frequency increased significantly from 0.63 ± 0.12 stools per day to 1.71 ± 0.13 stools per day after starting naloxegol (95% confidence interval [CI]: [0.75, 1.4], P < .001). There was no significant difference in the mean Withdrawal Assessment Tool 1 (WAT-1) score in the 24 hours before and after receiving the first dose (95% CI: [-0.25, 0.40], P = .63). This suggests naloxegol is effective in increasing stool output in critically ill children receiving opioids without an increase in opioid-withdrawal symptoms. It may be an effective adjunctive therapy for this population.
Related Concept Videos
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...

